Coronary Artery Disease and Risk of Major Vascular Events After Cerebral Infarction
Pierre Amarenco(Assistance Publique – Hôpitaux de Paris), Philippe Gabríel Steg(Mount Sinai Hospital), Julien Labreuche(ASTER), Grégory Ducrocq, Elena Meseguer(Université Paris Cité), Philippa C. Lavallée(Université Claude Bernard Lyon 1), Fernando Góngora‐Rivera(Inserm), Valérie Adraï(MACOM (United States)), Laurent J. Feldman(MACOM (United States)), Mikaël Mazighi(Inserm), Pierre‐Jean Touboul(Délégation Paris 7), Halim Abboud(Saint Joseph University), Jean‐Marc Olivot(Stanford University), Samina Ratani(MACOM (United States)), Bertrand Lapergue(Hôpital Foch), Jérôme Kusmierek(MACOM (United States)), Lucie Cabrejo(Délégation Paris 7), Jean-Michel Juliard(MACOM (United States)), Céline Guidoux(Inserm), Isabelle Klein(Délégation Paris 7), Arturo P Jaramillo(MACOM (United States))
Cited by 62
Related Papers
Ticagrelor versus Clopidogrel in Patients with Acute Coronary Syndromes
|New England Journal of Medicine|2009|7.1k
ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation
|European Heart Journal|2012|6.8k
Thrombectomy 6 to 24 Hours after Stroke with a Mismatch between Deficit and Infarct
|New England Journal of Medicine|2017|5.5k
Clinical End Points in Coronary Stent Trials
|Circulation|2007|5.4k
Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome
|New England Journal of Medicine|2018|3.5k